Glenmark's subsidiary Ichnos Sciences enters pact with Almirall for novel drug to treat autoimmune diseases

Under the agreement, Almirall is granted global rights to develop and commercialize this monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3m3HozT
via IFTTT